Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
165 results
Cited 15 times since 2021 (4.9 per year) source: EuropePMC
Frontiers in cardiovascular medicine, Volume 8, 28 4 2021, Pages 647785 Post-ischemic Myocardial Inflammatory Response: A Complex and Dynamic Process Susceptible to Immunomodulatory Therapies. Pluijmert NJ, Atsma DE, Quax PHA
Following acute occlusion of a coronary artery causing myocardial ischemia and implementing first-line treatment involving rapid reperfusion, a dynamic and balanced inflammatory response is initiated to repair and remove damaged cells. Paradoxically, restoration of myocardial blood flow exacerbates cell damage as a result of myocardial ischemia-reperfusion (MI-R) injury, which eventually provokes accelerated apoptosis. In the end, the infarct size still corresponds to the subsequent risk of deve... Abstract
Cited 8 times since 2021 (2.5 per year) source: EuropePMC
ESC heart failure, Volume 8, Issue 3, 2 1 2021, Pages 2306-2309 Reparative cell therapy for the heart: critical internal appraisal of the field in response to recent controversies. Povsic TJ, Sanz-Ruiz R, Climent AM, Bolli R, Taylor DA, Gersh BJ, Menasché P, Perin EC, Pompilio G, Atsma DE, Badimon L, DeMaria AN, Hare JM, Henry TD, Janssens S, Kastrup J, Torella D, Traverse JH, Willerson JT, Fernández-Avilés F
The concept that cell-based repair of myocardial injury might be possible was introduced almost two decades ago; however, the field of cardiovascular reparative medicine has been criticized as translation to clinically effective approaches has been slow. The recent retraction of a series of papers has further impacted perception of this area of research. As researchers, clinicians, and teachers in this field, we felt it incumbent to critically appraise the current state of cardiac cell repair, d... Abstract
European heart journal. Digital health, Volume 2, Issue 2, 22 4 2021, Pages 215-223 Potential of eHealth smart technology in optimization and monitoring of heart failure treatment in adults with systemic right ventricular failure. Nederend M, Zandstra TE, Kiès P, Jongbloed MRM, Vliegen HW, Treskes RW, Schalij MJ, Atsma DE, Egorova AD
Aims: Patients with a systemic right ventricle (sRV) in the context of transposition of the great arteries (TGA) after atrial switch or congenitally corrected TGA are prone to heart failure and arrhythmias. This study evaluated feasibility, patient adherence, and satisfaction of a smart technology-based care pathway for heart failure treatment optimization in these patients. Methods and results: Patients with symptomatic sRV failure eligible for initiation of sacubitril/valsartan were provided w... Abstract
Cited 6 times since 2020 (1.7 per year) source: Scopus
International journal of medical informatics, Volume 147, 13 2 2020, Pages 104364 A multi-stakeholder approach to eHealth development: Promoting sustained healthy living among cardiovascular patients. Breeman LD, Keesman M, Atsma DE, Chavannes NH, Janssen V, van Gemert-Pijnen L, Kemps H, Kraaij W, Rauwers F, Reijnders T, Scholte Op Reimer W, Wentzel J, Kraaijenhagen RA, Evers AWM, BENEFIT consortium
Background: Healthy living is key in the prevention and rehabilitation of cardiovascular disease (CVD). Yet, supporting and maintaining a healthy lifestyle is exceptionally difficult and people differ in their needs regarding optimal support for healthy lifestyle interventions. Objective: The goals of this study were threefold: to uncover stakeholders' needs and preferences, to translate these to core values, and develop eHealth technology based on these core values. Our primary research qu... Abstract
Cited 5 times since 2020 (1.4 per year) source: EuropePMC
JACC. Basic to translational science, Volume 5, Issue 12, 2 1 2020, Pages 1228-1239 Phosphorylcholine Antibodies Preserve Cardiac Function and Reduce Infarct Size by Attenuating the Post-Ischemic Inflammatory Response. Pluijmert NJ, de Jong RCM, de Vries MR, Pettersson K, Atsma DE, Jukema JW, Quax PHA
Phosphorylcholine monoclonal immunoglobulin G antibody attenuates the immediate post-ischemic inflammatory response by reducing the proinflammatory chemokine (C-C motif) ligand 2 chemokine and circulating Ly-6Chi monocytes. This subsequently enhances the post-ischemic repair process, resulting in limited adverse cardiac remodeling and preservation of cardiac function. Therefore, phosphorylcholine monoclonal immunoglobulin G antibody therapy may be a valid therapeutic approach against myocardial... Abstract
Cited 36 times since 2020 (10.3 per year) source: EuropePMC
Frontiers in nutrition, Volume 7, 19 3 2020, Pages 597600 The Impact of Obesity and Lifestyle on the Immune System and Susceptibility to Infections Such as COVID-19. de Frel DL, Atsma DE, Pijl H, Seidell JC, Leenen PJM, Dik WA, van Rossum EFC
Background: COVID-19 is a global challenge to healthcare. Obesity is common in patients with COVID-19 and seems to aggravate disease prognosis. In this review we explore the link between obesity, chronic disease, lifestyle factors and the immune system, and propose societal interventions to enhance global immunity. Search Strategy and Selection Criteria: We performed three literature searches using the keywords (1) coronavirus AND comorbidities, (2) comorbidities AND immune system, and (3) lifes... Abstract
Cited 10 times since 2020 (2.8 per year) source: EuropePMC
Scientific reports, Volume 10, Issue 1, 6 1 2020, Pages 16601 Effects on cardiac function, remodeling and inflammation following myocardial ischemia-reperfusion injury or unreperfused myocardial infarction in hypercholesterolemic APOE*3-Leiden mice. Pluijmert NJ, Bart CI, Bax WH, Quax PHA, Atsma DE
Many novel therapies to treat myocardial infarction (MI), yielding promising results in animal models, nowadays failed in clinical trials for several reasons. The most used animal MI model is based on permanent ligation of the left anterior descending (LAD) coronary artery in healthy mice resulting in transmural MI, while in clinical practice reperfusion is usually accomplished by primary percutaneous coronary interventions (PCI) limiting myocardial damage and inducing myocardial ischemia-reperf... Abstract
Cited 41 times since 2020 (11 per year) source: EuropePMC
Journal of medical Internet research, Volume 22, Issue 9, 2 1 2020, Pages e20953 Telemonitoring for Patients With COVID-19: Recommendations for Design and Implementation. Silven AV, Petrus AHJ, Villalobos-Quesada M, Dirikgil E, Oerlemans CR, Landstra CP, Boosman H, van Os HJA, Blanker MH, Treskes RW, Bonten TN, Chavannes NH, Atsma DE, Teng YKO
Despite significant efforts, the COVID-19 pandemic has put enormous pressure on health care systems around the world, threatening the quality of patient care. Telemonitoring offers the opportunity to carefully monitor patients with a confirmed or suspected case of COVID-19 from home and allows for the timely identification of worsening symptoms. Additionally, it may decrease the number of hospital visits and admissions, thereby reducing the use of scarce resources, optimizing health care capacit... Abstract
Cited 1 times since 2020 (0.2 per year) source: EuropePMC
Stem cell research, Volume 45, 8 2 2020, Pages 101764 Generation of two human induced pluripotent stem cell lines, LUMCi020-A and LUMCi021-A, from two patients with Catecholaminergic Polymorphic Ventricular Tachycardia carrying heterozygous mutations in the RYR2 gene. Meraviglia V, Arendzen CH, Freund C, Atsma DE, Mummery CL, Bellin M
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a malignant channelopathy associated with exercise- and stress-induced cardiac sudden death. The autosomal dominant form of CPVT is due to mutations in the ryanodine receptor 2 (RYR2) gene. We generated induced pluripotent stem cells (hiPSCs) from skin fibroblasts of two patients carrying the c.12441 G>T and c.14885 A>G RYR2 missense mutations, respectively, using non-integrating Sendai virus. These lines show the typical morp... Abstract
Cited 40 times since 2020 (9.7 per year) source: EuropePMC
JAMA network open, Volume 3, Issue 4, 1 1 2020, Pages e202165 Effect of Smartphone-Enabled Health Monitoring Devices vs Regular Follow-up on Blood Pressure Control Among Patients After Myocardial Infarction: A Randomized Clinical Trial. Treskes RW, van Winden LAM, van Keulen N, van der Velde ET, Beeres SLMA, Atsma DE, Schalij MJ
Importance: Smart technology via smartphone-compatible devices might improve blood pressure (BP) regulation in patients after myocardial infarction. Objectives: To investigate whether smart technology in clinical practice can improve BP regulation and to evaluate the feasibility of such an intervention. Design, setting, and participants: This study was an investigator-initiated, single-center, nonblinded, feasibility, randomized clinical trial conducted at the Department of Cardiology of the Lei... Abstract
Cited 10 times since 2019 (2 per year) source: EuropePMC
PloS one, Volume 14, Issue 6, 14 2 2019, Pages e0217582 Hypercholesterolemia affects cardiac function, infarct size and inflammation in APOE*3-Leiden mice following myocardial ischemia-reperfusion injury. Pluijmert NJ, den Haan MC, van Zuylen VL, Steendijk P, de Boer HC, van Zonneveld AJ, Fibbe WE, Schalij MJ, Quax PHA, Atsma DE
Background: Hypercholesterolemia is a major risk factor for ischemic heart disease including acute myocardial infarction. However, long-term effects of hypercholesterolemia in a rodent myocardial ischemia-reperfusion injury model are unknown. Therefore, the effects of diet-induced hypercholesterolemia on cardiac function and remodeling were investigated up to eight weeks after myocardial ischemia-reperfusion (MI-R) injury which was induced in either normocholesterolemic (NC-MI) or hypercholester... Abstract
Cited 4 times since 2019 (0.8 per year) source: EuropePMC
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, Volume 27, Issue 2, 1 1 2019, Pages 81-92 Intramyocardial bone marrow cell injection does not lead to functional improvement in patients with chronic ischaemic heart failure without considerable ischaemia. Mann I, Tseng CCS, Rodrigo SF, Koudstaal S, van Ramshorst J, Beeres SL, Dibbets-Schneider P, de Geus-Oei LF, Lamb HJ, Wolterbeek R, Zwaginga JJ, Fibbe WE, Westinga K, Bax JJ, Doevendans PA, Schalij MJ, Chamuleau SAJ, Atsma DE
Background: It has been suggested that bone marrow cell injection may have beneficial effects in patients with chronic ischaemic heart disease. However, previous trials have led to discrepant results of cell-based therapy in patients with chronic heart failure. The aim of this study was to evaluate the efficacy of intramyocardial injection of mononuclear bone marrow cells in patients with chronic ischaemic heart failure with limited stress-inducible myocardial ischaemia. Methods and results: Thi... Abstract
Cited 25 times since 2018 (4.1 per year) source: EuropePMC
Scientific reports, Volume 8, Issue 1, 30 5 2018, Pages 6753 Annexin A5 reduces infarct size and improves cardiac function after myocardial ischemia-reperfusion injury by suppression of the cardiac inflammatory response. de Jong RCM, Pluijmert NJ, de Vries MR, Pettersson K, Atsma DE, Jukema JW, Quax PHA
Annexin A5 (AnxA5) is known to have anti-inflammatory and anti-apoptotic properties. Inflammation and apoptosis are key processes in post-ischemic cardiac remodeling. In this study, we investigated the effect of AnxA5 on left ventricular (LV) function and remodeling three weeks after myocardial ischemia-reperfusion (MI-R) injury in hypercholesterolemic ApoE*3-Leiden mice. Using a mouse model for MI-R injury, we demonstrate AnxA5 treatment resulted in a 27% reduction of contrast-enhanced MRI asse... Abstract
Cited 10 times since 2017 (1.5 per year) source: EuropePMC
JMIR research protocols, Volume 6, Issue 9, 22 4 2017, Pages e186 Using Smart Technology to Improve Outcomes in Myocardial Infarction Patients: Rationale and Design of a Protocol for a Randomized Controlled Trial, The Box. Treskes RW, van Winden LA, van Keulen N, Atsma DE, van der Velde ET, van den Akker-van Marle E, Mertens B, Schalij MJ
Background: Recent evidence suggests that frequent monitoring using smartphone-compatible wearable technologies might improve clinical effectiveness and patient satisfaction of care. Objective: The aim of this study is to investigate the clinical effectiveness and patient satisfaction of a smart technology intervention in patients admitted with a ST elevation myocardial infarction (STEMI) or non-ST acute coronary syndrome (NST-ACS). Methods: In this single center, open, randomized controlled tri... Abstract
Cited 46 times since 2017 (6.8 per year) source: EuropePMC
Disease models & mechanisms, Volume 10, Issue 9, 1 1 2017, Pages 1039-1059 Human pluripotent stem cell models of cardiac disease: from mechanisms to therapies. Brandão KO, Tabel VA, Atsma DE, Mummery CL, Davis RP
It is now a decade since human induced pluripotent stem cells (hiPSCs) were first described. The reprogramming of adult somatic cells to a pluripotent state has become a robust technology that has revolutionised our ability to study human diseases. Crucially, these cells capture all the genetic aspects of the patient from which they were derived. Combined with advances in generating the different cell types present in the human heart, this has opened up new avenues to study cardiac disease in hu... Abstract
Cited 4 times since 2017 (0.6 per year) source: EuropePMC
Journal of interventional cardiology, Volume 30, Issue 5, 28 4 2017, Pages 440-447 Safety and efficacy of percutaneous intramyocardial bone marrow cell injection for chronic myocardial ischemia: Long-term results. Rodrigo SF, Mann I, van Ramshorst J, Beeres SL, Zwaginga JJ, Fibbe WE, Bax JJ, Schalij MJ, Atsma DE
Background: Intramyocardial injection of bone marrow cells (BMC) in refractory angina patients with chronic myocardial ischemia has shown to be safe and improve clinical status during short-term follow-up. However, scarce data are available on long-term (>12 months) safety and efficacy. Therefore, the occurrence of clinical events and the long-term clinical effects of intramyocardial BMC injection were evaluated in patients with chronic myocardial ischemia up to 10 years after treatment. Meth... Abstract
Cited 27 times since 2017 (3.9 per year) source: EuropePMC
Circulation. Cardiovascular imaging, Volume 10, Issue 7, 1 1 2017, Pages e005706 Global Longitudinal Strain and Left Atrial Volume Index Provide Incremental Prognostic Value in Patients With Hypertrophic Cardiomyopathy. Hiemstra YL, Debonnaire P, Bootsma M, van Zwet EW, Delgado V, Schalij MJ, Atsma DE, Bax JJ, Marsan NA
Background: Current methods for predicting adverse events in patients with hypertrophic cardiomyopathy are still limited. Left ventricular global longitudinal strain (GLS) and left atrial volume index (LAVI) have been recently proposed as novel prognostic factors in several cardiovascular diseases. The objective of this study was to evaluate the prognostic value of GLS and LAVI in patients with hypertrophic cardiomyopathy. Methods and results: Two-dimensional echocardiography was performed in 42... Abstract
Cited 62 times since 2017 (8.5 per year) source: EuropePMC
Circulation. Arrhythmia and electrophysiology, Volume 10, Issue 2, 1 1 2017, Pages e004052 Left Atrial Size and Function in Hypertrophic Cardiomyopathy Patients and Risk of New-Onset Atrial Fibrillation. Debonnaire P, Joyce E, Hiemstra Y, Mertens BJ, Atsma DE, Schalij MJ, Bax JJ, Delgado V, Marsan NA
Background: The value of left atrial (LA) diameter, volume, and strain to risk stratify hypertrophic cardiomyopathy patients for new-onset atrial fibrillation (AF) was explored. Methods and results: A total of 242 hypertrophic cardiomyopathy patients without AF history were evaluated by (speckle-tracking) echocardiography. During mean follow-up of 4.8±3.7 years, 41 patients (17%) developed new-onset AF. Multivariable analysis showed LA volume (≥37 mL/m2; hazard ratio, 2.68; 95% confidence interv... Abstract
Cited 7 times since 2016 (0.9 per year) source: EuropePMC
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, Volume 24, Issue 7-8, 1 1 2016, Pages 441-446 Redesigning healthcare: The 2.4 billion euro question? : Connecting smart technology to improve outcome of patients. Treskes RW, Van Der Velde ET, Atsma DE, Schalij MJ
Although it has been possible to transfer electrocardiograms via a phone line for more than 100 years, use of internet-based patient monitoring and communication systems in daily care is uncommon. Despite the introduction of numerous health-monitoring devices, and despite most patients having internet access, the implementation of individualised healthcare services is still limited. On the other hand, hospitals have invested heavily in massive information systems offering limited value for money... Abstract
Cited 4 times since 2016 (0.5 per year) source: EuropePMC
PloS one, Volume 11, Issue 4, 6 1 2016, Pages e0152938 Discrepant Results of Experimental Human Mesenchymal Stromal Cell Therapy after Myocardial Infarction: Are Animal Models Robust Enough? den Haan MC, van Zuylen VL, Pluijmert NJ, Schutte CI, Fibbe WE, Schalij MJ, Roelofs H, Atsma DE
Background: Human mesenchymal stromal cells (MSCs) have been reported to preserve cardiac function in myocardial infarction (MI) models. Previously, we found a beneficial effect of intramyocardial injection of unstimulated human MSCs (uMSCs) on cardiac function after permanent coronary artery ligation. In the present study we aimed to extend this research by investigating the effect of intramyocardial injection of human MSCs pre-stimulated with the pro-inflammatory cytokine interferon-gamma (iMS... Abstract